Skip to content Skip to footer

Jazz Pharmaceuticals and AbCellera Collaborate to Discover T-cell Engaging Multispecific Antibodies

Shots: Jazz has entered into a preclinical research collaboration, option & license agreement with AbCellera to discover & develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancer & other solid tumors, leveraging AbCellera’s antibody discovery engine  AbCellera will lead discovery & early-stage research for 2 initial programs, with a third to start within…

Read more

Know Your Investor: Orbimed (February’ 25 Edition)

Know Your Investor: Orbimed (February’ 25 Edition)

Shots:    The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors  In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing  For the complete report, contact us at connect@pharmashots.com  OrbiMed primarily…

Read more